DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

High Dose BAYA1040_Nifedipine: a Dose-comparative Study

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Nifedipine (Adalat, BAYA1040) (Drug); Nifedipine (Adalat, BAYA1040) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer


This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who are not at target blood pressure by BAYA1040_Nifedipine 40 mg once daily treatment.

Clinical Details

Official title: A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Efficacy changes measured by sitting diastolic blood pressure (DBP)

Secondary outcome:

Efficacy changes measured by sitting systolic blood pressure (SBP)

Achievement rate: Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines

Responder rate: Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP


Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- 20 years or older

- Japanese male or female

- Outpatient with essential hypertension

- Patients whose sitting diastolic blood pressure (DBP) is 90 mmHg or more despite more

than 4 weeks of treatment with antihypertensive drug Exclusion Criteria:

- Sitting diastolic blood pressure (DBP) is 110 mmHg or more or sitting systolic blood

pressure (SBP) is 180 mmHg or more

- Patients with secondary hypertension or hypertensive emergency

Locations and Contacts

Shizuoka 421-0193, Japan

Hirosaki, Aomori 036-8082, Japan

Kamagaya, Chiba 273-0100, Japan

Asahikawa, Hokkaido 070-0061, Japan

Asahikawa, Hokkaido 078-8214, Japan

Sapporo, Hokkaido 007-0841, Japan

Sapporo, Hokkaido 003-0825, Japan

Sapporo, Hokkaido 004-0004, Japan

Sapporo, Hokkaido 003-0026, Japan

Sapporo, Hokkaido 062-0053, Japan

Sapporo, Hokkaido 063-0841, Japan

Sapporo, Hokkaido 064-0803, Japan

Sapporo, Hokkaido 064-0807, Japan

Kawasaki, Kanagawa 210-0852, Japan

Daito, Osaka 574-0074, Japan

Kishiwada, Osaka 596-8522, Japan

Yao, Osaka 581-0011, Japan

Tokorozawa, Saitama 359-1141, Japan

Hachioji, Tokyo 192-0046, Japan

Meguro, Tokyo 152-0031, Japan

Minato, Tokyo 105-7390, Japan

Minato, Tokyo 108-0075, Japan

Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: January 2011
Last updated: January 28, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017